Human evidence first
Randomised human trials carry more weight than mechanisms or laboratory findings alone.
Every active is disclosed with its exact dose. Explore the human evidence behind the ingredients, how closely each study matches Ava, and where the science is still developing.
Evidence, read in context.
“Science-backed” means little without the study design, population, ingredient form and dose. We show the match as well as the limitations.
Randomised human trials carry more weight than mechanisms or laboratory findings alone.
We compare the researched amount and extract specification with the amount and form in Ava.
Mixed findings, small samples and different populations are shown—not edited out.
Illustrative model only. This graph explains the formulation strategy; it is not measured clinical outcome data for the finished Ava product and does not predict an individual response.
Search selected human trials and evidence reviews relevant to Ava’s ingredients. Filter by ingredient or by the role it plays in the formula.
Reviews may include trials listed separately. The entry count is not a count of independent experiments.
95 older adults · 1,000 mg/day · 3 months
The initial benefit was limited to participants with less efficient memory. A 32-person follow-up used 2,000 mg/day. Both doses exceed ava’s 500 mg; this is not evidence for all age groups.Read study75 participants · 250 or 500 mg/day · 28 days
Attention and motor-speed measures improved versus placebo. This short study involved adolescent males and a specific citicoline product; it does not establish adult outcomes or recommend ava for children.Read study24 completed · 1,000 mg/day · 6 weeks per treatment
NR increased blood-cell NAD+ and was generally well tolerated. This biomarker result is not proof of better everyday energy; the dose was above ava’s 300 mg.Read study40 men · 2,000 mg/day · 12 weeks
No improvement in insulin sensitivity, resting energy expenditure or body composition versus placebo. The population and dose differ from ava; NAD+ biology does not guarantee a metabolic benefit.Read study13 adults · 1,000 mg/day · 6 weeks per treatment
Some muscle metabolites changed, but insulin sensitivity and mitochondrial function did not improve. A small trial in overweight or obese adults, at a higher dose than ava.Read studyFruiting-body supplement · 12 weeks
One of three cognitive tests improved; the other tests did not show the same benefit. This preparation was not ava’s extract, and the trial does not establish dementia prevention.Read study30 women randomised · 2 g/day powder · 4 weeks
Some individual symptom scores differed, but overall depression and sleep-score changes did not significantly differ from placebo. Only 26 participants were analysed; powder is not equivalent to ava’s extract.Read study41 adults · 200 mg/day · 14 days
Blood CoQ10 increased, but the endurance finding was a non-significant trend (p = 0.06). The fast-melt preparation and 200 mg dose differ from ava’s 100 mg.Read study100 athletes · 300 mg/day · 6 weeks
Power at the tested lactate threshold improved more than placebo during training. This used ubiquinol, not ava’s ubiquinone, at three times the dose; the forms cannot be assumed equivalent.Read study96 participants · Ages 71–88 · Clinical population
The authors reported improvements in fatigue and function. Results in older patients cannot establish everyday benefits in healthy younger adults; the abstract does not specify the dose or duration.Read study90 patients · ALCAR arm: 2 g/day · 24 weeks
Mental-fatigue scores improved in the acetyl-L-carnitine arm, but there was no placebo group or blinding. Clinical population and dose differ substantially from ava; no treatment benefit for ava is established.Read study7 performance studies · 17 side-effect studies
The pooled performance estimate was small and its confidence interval included no effect. Doses and administration methods varied; these findings do not establish a benefit from ava’s 600 mg oral dose.Read analysis37 papers · 1,388 participants
Acute NAC did not significantly improve lactate, oxygen uptake or several other recovery markers. Biomarker research with varied protocols is not proof of better recovery from ava.Read analysis11 trained cyclists · 20 mg/kg · Acute oral dosing
No improvement in either cycling performance test versus placebo. This small trial used body-weight-based dosing and a specific exercise protocol, not ava’s daily formulation.Read study96 adults · 6 or 12 mg/day · 12 weeks
Some scores improved over time, but the trial did not establish a significant cognitive difference versus placebo. Studied doses bracket ava’s 8 mg; matching the ingredient alone is not enough.Read study54 participants · 8 mg/day · 8 weeks
No significant overall differences on cognitive tests; an age subgroup showed a signal. The bacterial extract also differs from ava’s ingredient source, despite the matching 8 mg dose.Read study21 randomised · 4 mg/day · 28 days
Cycling time improved versus placebo, but only 14 riders completed the trial. A small sport-specific result at half ava’s dose does not establish a general energy benefit.Read study60 participants · SHR-5 576 mg/day · 28 days
Some fatigue and attention measures improved versus placebo. Participants had fatigue syndrome; this standardised extract and dose differ from ava’s 75 mg and do not establish a treatment claim for ava.Read study11 controlled studies · Mixed populations
Findings were inconsistent. All included studies had high or unclear risk of bias, so the review could not establish reliable fatigue benefits; it is not evidence for ava’s finished formula.Read review18 participants · 3 mg/kg · Single dose
Cycling time and perceived exertion improved, but cognition and other measures did not significantly change. A small acute trial with weight-based dosing, not a test of ava’s 75 mg serving.Read study30 healthy adults · G115 200 or 400 mg · Single dose
The 200 mg dose improved one arithmetic task and perceived mental fatigue. Small, task-specific findings with G115 cannot be transferred directly to ava’s 75 mg ginseng.Read study30 adults · G115 200 or 400 mg/day · 8-day periods
Effects depended on dose: 400 mg improved some measures, while 200 mg slowed arithmetic responses. Repeated use added no clear benefit; extract and doses differ from ava.Read study90 participants · 1 or 2 g/day extract · 4 weeks
Total fatigue scores did not significantly differ from placebo; some mental-fatigue measures improved. Clinical population and gram-level doses differ substantially from ava’s 75 mg.Read study9 eligible trials · 5 with extractable results
The review found insufficient convincing evidence for cognitive enhancement in healthy people. Different doses, products and tests prevented pooled analysis; selected positive trials do not settle the question.Read review100 participants · 500 mg/day · 12 weeks
Relevant dose; population had age-associated memory impairment.Read study140 participants · 100–1,000 mg/day · 8 weeks
Shows a biomarker effect; does not establish a subjective energy benefit.Read study30 participants · 3 g/day powder · 16 weeks
Promising outcome; form, dose and population differ from Ava.Read study18 healthy adults · 3 g extract · Single dose
No overall improvement in cognition or mood; one motor-task result improved. The 3 g, 10:1 extract differs from ava’s 750 mg fruiting-body extract.Read study41 completed · 1.8 g/day · 28 days
A faster Stroop-task result, but mixed memory findings and no clear overall cognitive benefit. The stress finding was a non-significant trend. Dose and mushroom preparation differ from ava.Read study17 participants · 100 or 300 mg/day · 8 days
Small sample; strongest signal appeared at the higher dose.Read study13 randomised trials · 1,126 participants
Pooled fatigue scores improved, but populations, doses and durations varied. Combination-product results were not significant; this does not establish a benefit for ava’s finished formula.Read analysis121 randomised · 500 mg/day · 6 weeks per treatment
No significant symptom or quality-of-life benefit versus placebo. This clinical population and dose differ from ava’s 100 mg per serving; it is not evidence for treating long COVID.Read studyCochrane evidence review
Too little reliable evidence for conclusions in healthy adults.Read reviewReview of clinical evidence
The literature was heterogeneous and underpowered for firm conclusions.Read review0, 2 or 8 mg/day · 8 weeks
Dose-aligned biomarker research; not a direct performance outcome.Read study11 RCTs · 346 healthy participants
Cognitive accuracy was marginal; reaction time was not significant.Read analysis48 nursing students · 364–728 mg/day · 42 days
The primary result favoured placebo—an important contradictory finding.Read studyNarrative review · 16 human trials · 363 participants
Findings varied by exercise task, dose and extract. Studied regimens were generally above ava’s 75 mg per serving; benefits cannot be assumed for ava.Read review118 participants · 400 mg/day · 12 weeks
Symptoms improved over time, but there was no placebo group to establish a treatment effect. The clinical population, WS 1375 extract and 400 mg dose differ from ava’s 75 mg serving.Read studyPilot human crossover research
Results are extract-specific and cannot be transferred automatically.Read studyTry a broader search or reset the filters.
The research above evaluates individual ingredients, often in different populations, forms, doses and durations. It does not prove that the finished Ava formula will produce identical outcomes.
Ava is a food supplement, not a medicine, and is not intended to diagnose, treat, cure or prevent disease.
Explore Focused Energy